Ocular Adverse Events Associated With Mek Inhibitors

Abstract

Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors. Methods: We conducted a scientific literature search using the PubMed database up to July 2018 with the terms “MEK inhibitors” with a “review” filter and “MEK inhibitors” with a “clinical trials” filter. Phase I–III experimental studies and reviews were selected. Current principles and techniques for diagnosing and managing MEK inhibitor retinopathy and other OAEs are discussed. Results: In patients treated with MEK inhibitors, including asymptomatic patients, OAEs occur with an incidence of up to 90%. Mild to severe ophthalmic toxicities are described, including visual disturbances, a 2-line decrease in Snellen visual acuity, dry eye symptoms, ocular adnexal abnormalities, visual field defects, panuveitis, and retinal toxicities, such as different degrees of MEK-associated retinopathy, vascular injury, and retinal vein occlusion. Conclusion: MEK inhibitors can lead to different degrees of retinal, uveal, and adnexal OAE, causing visual disturbances or discomfort. One of the most relevant OAE of MEK therapy is MEK inhibitor–associated retinopathy (MEKAR), which is usually mild, self-limited, and may subside after continuous use of the drug for weeks or months, or discontinuation, thereby restoring the normal visual function of the retina, with some exceptions. Ocular adverse events are often associated with other systemic adverse effects that can modify the dosage of treatment, so the communication with the oncologist is fundamental.

Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors

“…It has been suggested that BRAF/MEK inhibition might upregulate inflammatory genes in macrophages and T cells and synergize PD-1 blockade. 5 Given that this new symptoms appeared 1 month after the most recently introduced BRAF/ MEK treatment, the possibility of an additive neurotoxic ocular adverse effect 6 and worsening of ankle and knee pain from these treatments has to be considered. [7][8][9] However, BRAF/MEK inhibitors were not stopped and recovery occurred during treatment with these agents.…”

A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses

“…A rare toxicity of EGFR inhibitor therapy includes trichomegaly, or abnormal growth of the eyelashes, which can lead to back-growth of the lashes onto the conjunctiva and cornea, leading to corneal ulcerations in severe cases [ 78 ]. One of the more concerning toxicities is retinal vein occlusion associated with the mitogen-activated protein kinase (MEK) inhibitors (trametinib, cobimetinib, binimetinib) [ 79 ]. Ocular toxicity can occur months following the initiation of KI therapy [ 78 , 80 ].…”

Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review

“…[72] Visual function is usually restored with no permanent visual loss in the majority of those affected. [76] BRAF inhibitors Dabrafenib, vemurafenib: BRAF inhibitors also act along the MAP kinase pathway and are used in advanced melanomas. Examples include dabrafenib and vemurafenib.…”